PT  - JOURNAL ARTICLE
AU  - John A. Biesemeier
AU  - Melissa J. Beck
AU  - Hanna Silberberg
AU  - Nicole R. Myers
AU  - John M. Ariano
AU  - Eric S. Bodle
AU  - Daniel W. Sved
AU  - Sylvia Jacobi
AU  - Donald G. Stump
AU  - Marcia Hardy
AU  - Todd Stedeford
TI  - Effects of Dose, Administration Route, and/or Vehicle on Decabromodiphenyl Ether Concentrations in Plasma of Maternal, Fetal, and Neonatal Rats and in Milk of Maternal Rats
AID  - 10.1124/dmd.110.033431
DP  - 2010 Oct 01
TA  - Drug Metabolism and Disposition
PG  - 1648--1654
VI  - 38
IP  - 10
4099  - http://dmd.aspetjournals.org/content/38/10/1648.short
4100  - http://dmd.aspetjournals.org/content/38/10/1648.full
SO  - Drug Metab Dispos2010 Oct 01; 38
AB  - The effects of route and vehicle on blood and milk levels of decabromodiphenyl ether (DecaBDE; CASRN 1163-19-5) were investigated in the rat to assist in the design and conduct of a developmental neurotoxicity study. Blood plasma and/or milk concentrations were determined in dams, fetuses, and/or nursing pups after repeated DecaBDE administration by gavage throughout gestation or gestation and lactation using corn oil (CO) or soyaphospholipon/Lutrol F 127-water (SPL) as the vehicle. The impact of vehicle on plasma levels was also investigated in pups derived from naive dams after a single postnatal dose. This study reports for the first time fetal and neonatal plasma concentrations concurrent with those of maternal plasma and/or milk. Higher concentrations of DecaBDE were achieved in plasma and in milk with CO than with SPL. Furthermore, pups derived from dams treated with only SPL were lower in body weight, compared with those from dams treated with either CO, CO and DecaBDE, or SPL and DecaBDE. The study further shows that exposure to DecaBDE is relatively consistent across the dose range of 100 to 1000 mg/(kg · day) when administered in CO.